CO2023007624A2 - Derivados de n-(imidazo)[1,2-b]piridazin-3-il)-1-ciclohexil-2h-indazol-5-carboxamida y de n-(pirazolo[1,5-a]pirimidin-3-il)-1-ciclohexil-2h-indazol-5-carboxamida como inhibidores de irak4 para el tratamiento del asma - Google Patents
Derivados de n-(imidazo)[1,2-b]piridazin-3-il)-1-ciclohexil-2h-indazol-5-carboxamida y de n-(pirazolo[1,5-a]pirimidin-3-il)-1-ciclohexil-2h-indazol-5-carboxamida como inhibidores de irak4 para el tratamiento del asmaInfo
- Publication number
- CO2023007624A2 CO2023007624A2 CONC2023/0007624A CO2023007624A CO2023007624A2 CO 2023007624 A2 CO2023007624 A2 CO 2023007624A2 CO 2023007624 A CO2023007624 A CO 2023007624A CO 2023007624 A2 CO2023007624 A2 CO 2023007624A2
- Authority
- CO
- Colombia
- Prior art keywords
- carboxamide
- indazol
- formula
- cyclohexyl
- pyridazin
- Prior art date
Links
- 229940127590 IRAK4 inhibitor Drugs 0.000 title abstract 2
- 208000006673 asthma Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000011594 Autoinflammatory disease Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- 201000005569 Gout Diseases 0.000 abstract 1
- 201000002481 Myositis Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- HLUMPUAUCWMXKL-UHFFFAOYSA-N O=C(C1=CC2=CN(C(CC3)CCC33NCCC3)N=C2C=C1)NC1=C2N=CC=CN2N=C1 Chemical compound O=C(C1=CC2=CN(C(CC3)CCC33NCCC3)N=C2C=C1)NC1=C2N=CC=CN2N=C1 HLUMPUAUCWMXKL-UHFFFAOYSA-N 0.000 abstract 1
- OWWONESKONXVFI-UHFFFAOYSA-N O=C(C1=CC2=CN(C(CC3)CCC33NCCC3)N=C2C=C1)NC1=CN=C2N1N=CC=C2 Chemical compound O=C(C1=CC2=CN(C(CC3)CCC33NCCC3)N=C2C=C1)NC1=CN=C2N1N=CC=C2 OWWONESKONXVFI-UHFFFAOYSA-N 0.000 abstract 1
- PIEFBWDHIVDFLX-UHFFFAOYSA-N O=C(C1=CC=C2N(C3CCCCC3)NCC2=C1)NC1=C2N=CC=CN2N=C1 Chemical compound O=C(C1=CC=C2N(C3CCCCC3)NCC2=C1)NC1=C2N=CC=CN2N=C1 PIEFBWDHIVDFLX-UHFFFAOYSA-N 0.000 abstract 1
- SLFYLMUBNWHOSJ-UHFFFAOYSA-N O=C(C1=CC=C2N(C3CCCCC3)NCC2=C1)NC1=CN=C2N1N=CC=C2 Chemical class O=C(C1=CC=C2N(C3CCCCC3)NCC2=C1)NC1=CN=C2N1N=CC=C2 SLFYLMUBNWHOSJ-UHFFFAOYSA-N 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 208000021386 Sjogren Syndrome Diseases 0.000 abstract 1
- 201000009594 Systemic Scleroderma Diseases 0.000 abstract 1
- 206010042953 Systemic sclerosis Diseases 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063199160P | 2020-12-10 | 2020-12-10 | |
| PCT/EP2021/084916 WO2022122876A1 (en) | 2020-12-10 | 2021-12-09 | N-(imidazo[1,2-b]pyridazin-3-yl)-1-cyclohexyl-2h-indazole-5-carboxamide and n-(pyrazolo[1,5-a]pyrimidin-3-yl)-1-cyclohexyl-2h-indazole-5-carboxamide derivatives as irak4 inhibitors for the treatment of asthma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023007624A2 true CO2023007624A2 (es) | 2023-06-30 |
Family
ID=79230946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0007624A CO2023007624A2 (es) | 2020-12-10 | 2023-06-09 | Derivados de n-(imidazo)[1,2-b]piridazin-3-il)-1-ciclohexil-2h-indazol-5-carboxamida y de n-(pirazolo[1,5-a]pirimidin-3-il)-1-ciclohexil-2h-indazol-5-carboxamida como inhibidores de irak4 para el tratamiento del asma |
Country Status (33)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7555519B2 (ja) * | 2022-02-14 | 2024-09-24 | アストラゼネカ・アクチエボラーグ | Ｉｒａｋ４阻害剤 |
| US20250326757A1 (en) * | 2022-05-26 | 2025-10-23 | Astrazeneca Ab | Solid forms of heterocyclylamides as irak4 inhibitors |
| TW202508568A (zh) | 2023-04-07 | 2025-03-01 | 瑞典商阿斯特捷利康公司 | Ｉｒａｋ４蛋白水解靶向嵌合體 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110003219A (zh) | 2010-07-13 | 2019-07-12 | 弗·哈夫曼-拉罗切有限公司 | 作为irak4调节剂的吡唑并[1,5a]嘧啶和噻吩并[3,2b]嘧啶衍生物 |
| BR112013015460B1 (pt) | 2010-12-20 | 2022-01-25 | Merck Serono S.A. | Derivados de indazolil triazol, kit, e composição farmacêutica |
| BG111378A (bg) * | 2013-01-14 | 2015-01-30 | Николай Цветков | Субституирани индазолови производни като in-vitro mao-b инхибитори |
| DK2970139T3 (en) | 2013-03-15 | 2018-08-13 | Biomarin Pharm Inc | HDAC inhibitors |
| EP3092226B1 (en) | 2014-01-10 | 2019-03-13 | Aurigene Discovery Technologies Limited | Indazole compounds as irak4 inhibitors |
| DK3126330T3 (en) | 2014-04-04 | 2019-04-23 | Pfizer | BICYCLE-FUSED HETEROARYL OR ARYL COMPOUNDS AND USE THEREOF AS IRAC4 INHIBITORS |
| JO3705B1 (ar) | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
| TW201701879A (zh) | 2015-04-30 | 2017-01-16 | 拜耳製藥公司 | Ｉｒａｋ４抑制劑組合 |
| CN108024971A (zh) | 2015-07-15 | 2018-05-11 | 奥列基因发现技术有限公司 | 作为irak-4抑制剂的取代的氮杂化合物 |
| JP2018524372A (ja) | 2015-07-15 | 2018-08-30 | アウリジーン ディスカバリー テクノロジーズ リミテッド | Ｉｒａｋ−４阻害剤としてのインダゾール及びアザインダゾール化合物 |
| CN105503863A (zh) * | 2015-12-11 | 2016-04-20 | 南京华威医药科技开发有限公司 | 新型抗肿瘤化合物 |
| CN108473498B (zh) | 2015-12-22 | 2021-11-02 | 豪夫迈·罗氏有限公司 | 作为IRAK4调节剂的吡唑并[1,5a]嘧啶衍生物 |
| WO2017148902A1 (de) | 2016-03-03 | 2017-09-08 | Bayer Pharma Aktiengesellschaft | Neue 2-substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln |
| US10059708B2 (en) | 2016-04-26 | 2018-08-28 | Northwestern University | Therapeutic targeting of the interleukin 1 receptor-associated kinase 4 (IRAK4) in leukemias characterized by rearrangements in the mixed lineage leukemia gene (MLL-r) |
| SG10202011653WA (en) | 2016-06-01 | 2020-12-30 | Bayer Pharma AG | Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases |
| EP3642201A1 (en) | 2017-06-21 | 2020-04-29 | H. Hoffnabb-La Roche Ag | Isoindolinone derivatives as irak4 modulators |
| JP2020524692A (ja) | 2017-06-21 | 2020-08-20 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｉｒａｋ４調節因子としてのベンゾフラン |
| US20230002361A1 (en) | 2019-06-27 | 2023-01-05 | Biogen Ma Inc. | 2h-indazole derivatives and their use in the treatment of disease |
| JP7576581B2 (ja) | 2019-06-27 | 2024-10-31 | バイオジェン・エムエイ・インコーポレイテッド | イミダゾ［１，２－ａ］ピリジニル誘導体及び疾患の処置におけるそれらの使用 |
-
2021
- 2021-12-01 US US17/457,249 patent/US11866405B2/en active Active
- 2021-12-09 PE PE2023001857A patent/PE20240684A1/es unknown
- 2021-12-09 TW TW110145977A patent/TWI902994B/zh active
- 2021-12-09 HR HRP20241312TT patent/HRP20241312T1/hr unknown
- 2021-12-09 SM SM20240417T patent/SMT202400417T1/it unknown
- 2021-12-09 KR KR1020237023107A patent/KR20230118153A/ko active Pending
- 2021-12-09 SI SI202130206T patent/SI4259632T1/sl unknown
- 2021-12-09 RS RS20241183A patent/RS66095B1/sr unknown
- 2021-12-09 IL IL303356A patent/IL303356B1/en unknown
- 2021-12-09 JP JP2023535016A patent/JP7749015B2/ja active Active
- 2021-12-09 PL PL21836097.2T patent/PL4259632T3/pl unknown
- 2021-12-09 LT LTEPPCT/EP2021/084916T patent/LT4259632T/lt unknown
- 2021-12-09 HU HUE21836097A patent/HUE068584T2/hu unknown
- 2021-12-09 MA MA62535A patent/MA62535B1/fr unknown
- 2021-12-09 DK DK21836097.2T patent/DK4259632T3/da active
- 2021-12-09 WO PCT/EP2021/084916 patent/WO2022122876A1/en not_active Ceased
- 2021-12-09 PT PT218360972T patent/PT4259632T/pt unknown
- 2021-12-09 ES ES21836097T patent/ES2989489T3/es active Active
- 2021-12-09 MX MX2023006816A patent/MX2023006816A/es unknown
- 2021-12-09 CR CR20230264A patent/CR20230264A/es unknown
- 2021-12-09 UA UAA202303173A patent/UA130417C2/uk unknown
- 2021-12-09 CN CN202180082181.5A patent/CN116583285B/zh active Active
- 2021-12-09 CA CA3203569A patent/CA3203569A1/en active Pending
- 2021-12-09 EP EP21836097.2A patent/EP4259632B1/en active Active
- 2021-12-09 FI FIEP21836097.2T patent/FI4259632T3/fi active
- 2021-12-09 AU AU2021395816A patent/AU2021395816B2/en active Active
- 2021-12-10 AR ARP210103432A patent/AR124303A1/es unknown
- 2021-12-10 UY UY0001039561A patent/UY39561A/es unknown
-
2023
- 2023-06-08 CL CL2023001662A patent/CL2023001662A1/es unknown
- 2023-06-09 CO CONC2023/0007624A patent/CO2023007624A2/es unknown
- 2023-06-09 DO DO2023000119A patent/DOP2023000119A/es unknown
- 2023-07-05 ZA ZA2023/06848A patent/ZA202306848B/en unknown
- 2023-07-05 EC ECSENADI202350553A patent/ECSP23050553A/es unknown
- 2023-11-02 US US18/500,155 patent/US12448385B2/en active Active
-
2025
- 2025-09-29 US US19/343,252 patent/US20260092069A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2023007624A2 (es) | Derivados de n-(imidazo)[1,2-b]piridazin-3-il)-1-ciclohexil-2h-indazol-5-carboxamida y de n-(pirazolo[1,5-a]pirimidin-3-il)-1-ciclohexil-2h-indazol-5-carboxamida como inhibidores de irak4 para el tratamiento del asma | |
| CN115925705B (zh) | 杂芳类衍生物调节剂、其制备方法和应用 | |
| AU2020293021B2 (en) | PRMT5 inhibitors | |
| AU2023201522B2 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| CN102711476B (zh) | 新的三环化合物 | |
| PE20211001A1 (es) | Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b | |
| JP2017503867A5 (enExample) | ||
| JP2014531458A5 (enExample) | ||
| RU2015131148A (ru) | СОЕДИНЕНИЯ, ГЕТЕРОБИЦИКЛО-ЗАМЕЩЕННЫЕ-[1, 2, 4]ТРИАЗОЛО[1, 5c]ХИНАЗОЛИН-5-АМИНА, ОБЛАДАЮЩИЕ СВОЙСТВАМИ А2А АНТАГОНИСТОВ | |
| KR20120047924A (ko) | Ｐｉ3ｋ 저해물질로서의 피리미디논 | |
| MX2012006381A (es) | Nuevos compuestos triciclicos. | |
| CA2713718A1 (en) | Pyrrolopyrazine kinase inhibitors | |
| JP2016504363A5 (enExample) | ||
| WO2012149280A2 (en) | Novel tricyclic compounds | |
| EP2299821A1 (en) | Novel tricyclic compounds | |
| CA2681093A1 (en) | Compounds for the treatment of hepatitis c | |
| CA2620223A1 (en) | Novel imidazo based heterocycles | |
| WO2013043826A1 (en) | Tricyclic compounds useful as protein kinase inhibitors | |
| CA3189706A1 (en) | Casein kinase 1 delta modulators | |
| Dyachenko et al. | Fused pyrimidine systems: XIII. Synthesis and some transformations of 1, 3-thiazolo (thiazino)-fused pyrido [3, 4-d] pyrimidines | |
| CN112867715B (zh) | 作为腺苷受体拮抗剂的5-氮杂吲唑衍生物 | |
| RU2017103508A (ru) | Трициклические триазольные соединения | |
| EA052277B1 (ru) | Трициклические гетероциклические производные, их композиции и использование | |
| BR122025019954A2 (pt) | Compostos, composições farmacêuticas e seus usos para o tratamento de distúrbios inflamatórios | |
| BR112020007541B1 (pt) | Compostos, composições farmacêuticas e seus usos para o tratamento de distúrbios inflamatórios |